Pfizer

Complaints & Reviews on USAComplaints

USAComplaints currently maintains 11 historical complaints about Pfizer, published between 2006 and 2012. No approved complaints have been published on this site during the last three years. For a current reputation snapshot, see the independent sources below.

• Pfizer Tetracycline stained teeth - Tetracycline Stained TeethPublished Jul 6, 2012 · Historical consumer allegation
• Pfizer Tetracycline Stained TeethPublished Jul 6, 2012 · Historical consumer allegation
• Stanning of teethPublished Jun 12, 2012 · Historical consumer allegation
• Advertisement on TV states that you can get a $4:00 Drug Co-Pay card which implies that all you will have to pay would be the $4:00 Co-Pay, However in reality there is a $50.00 cap per monthPublished Jan 11, 2012 · Historical consumer allegation
• DiscriminationPublished Apr 25, 2011 · Historical consumer allegation
• BOYCOTT PFIZER tetracycline stained teethPublished Jan 19, 2010 · Historical consumer allegation
• Failed to honor dewormer rebate claimPublished Oct 15, 2009 · Historical consumer allegation
• Tetracycline staining of the teethPublished Sep 17, 2009 · Historical consumer allegation
• Charged me $349 for a prescripition for lipitor and refused to help me as they advertised new york new yorkPublished Jun 2, 2009 · Historical consumer allegation
• Rebate offer another way to ripoff customersPublished Jul 25, 2007 · Historical consumer allegation
• Pfizer is destroying womens bodies, Bones and lives ripoffPublished Oct 4, 2006 · Historical consumer allegation

Complaint Themes

Each tag reflects a complaint's single primary theme (not every angle it raised), and complaints outside any problem theme — a positive report, or one later retracted by its author — aren't tagged. Counts may total less than the full complaint count above.

Independent Sources

Shown for context — not merged with USAComplaints' own numbers.

Contacts

• Official website: https://www.pfizer.com/
• Customer service and product inquiries (Mon-Fri 9:00 a.m.-7:00 p.m. EST, per Pfizer): 800-879-3477
• Adverse events (U.S. only, per Pfizer's reporting page); also Pfizer Medical Information (Available : 800-438-1985
• Pfizer safety reporting portal (adverse events for Pfizer products, incl. Pfizer-BioNTech COVID-19 v: https://www.pfizersafetyreporting.com
• Pfizer RxPathways (patient assistance and savings programs): https://www.pfizerrxpathways.com/
• Pfizer Patient Assistance Program (RxPathways): 866-706-2400
• Corporate switchboard (SEC filing): 212-733-2323 2 complaints mention this number

Locations

Pfizer medicine question, side effect, recall or claim? Where to go

Pfizer Inc. makes prescription medicines and vaccines; it is not a pharmacy or an insurer. The right channel depends on the problem:

• Side effect or suspected adverse event. Pfizer's page says patients should first ask their healthcare provider for medical advice, then report to Pfizer at pfizersafetyreporting.com (options for the Pfizer-BioNTech COVID-19 vaccine, Paxlovid and "All other Pfizer products") or, in the United States, by calling 1-800-438-1985. Medicines other than vaccines: the same page adds "If you prefer, you may contact the U.S. Food & Drug Administration (FDA) directly" at www.fda.gov/Safety/MedWatch or 1-800-FDA-1088; FDA describes MedWatch as its reporting program for "health professionals, patients and consumers" (www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program). Vaccines: FDA's MedWatch page says vaccines "use different reporting pathways"; the vaccine reporting system run by CDC and FDA is VAERS (vaers.hhs.gov/reportevent.html), which states "Anyone can report an adverse event to VAERS" and lists 1-800-822-7967 for help with reporting. A report to Pfizer, FDA or VAERS is not a treatment service. In an emergency, call 911 or your local emergency number. Pfizer's adverse-events page lists the number 1-800-438-1985 without hours. Pfizer's Medical Information page (pfizermedical.com/patient, read September 30, 2026) lists the same number for speaking with a Medical Information professional, "Available 9AM-5PM ET Monday to Friday; excluding holidays." Pfizer's April 2022 Accupril recall notice described the same number with option 1, "Pfizer Drug Safety" ("To report adverse events and product complaints", "24 hours a day; 7 days a week"), and option 3, "Pfizer Medical Information" ("For medical questions regarding the product", "Mon.-Fri. 8 am-9 pm ET"); those options and hours come from that 2022 notice and were not on the current Pfizer pages reviewed.
• Product-quality problem or general product question. Pfizer's Contact Us page lists 1-800-879-3477 ("Customer Service and Product Inquiries", Monday through Friday 9:00 a.m. to 7:00 p.m. EST) and an online contact form. FDA's Oxbryta alert encourages patients to report "adverse events or quality problems" to MedWatch.
• A recall. Compare the exact product name, strength, NDC and lot number on your package with the notices summarized below and with FDA's Enforcement Report search (www.accessdata.fda.gov/scripts/ires/index.cfm) or FDA's Drug Recalls page; a recall listed here from 2021 or 2022 does not mean a product bought today is affected. The Chantix, Accupril and Accuretic notices tell patients to consult their healthcare provider about alternatives; they do not tell patients to stop on their own. The consumer return contacts named in those historical notices were Stericycle at 888-276-6166 (Chantix, September 2021), Sedgwick at 888-345-0481 (Accupril, April 2022) and Sedgwick at 888-843-0247 (Accuretic, March 2022); check that a notice is still open before relying on a number. FDA's page for the Accupril notice states "This recall has been completed and FDA has terminated this recall."
• Cost of a Pfizer medicine. Pfizer RxPathways describes a Patient Assistance Program (call 1-866-706-2400), an Institutional program through clinics, and separate co-pay and savings offers. Its Program Finder (www.PfizerRxPathways.com) and its toll-free line, 1-844-989-PATH (7284), connect patients with a Medicine Access Counselor. The RxPathways pages state the Patient Assistance Program's income limit in more than one way (see the FAQ below), so confirm the rule for your medicine with the program; the caregivers page says "Commercially insured patients are not eligible."
• Chantix purchase refund. A $44 million class settlement covers retail Chantix purchases from September 29, 2015 through September 17, 2021. The claim, opt-out and objection deadline stated on the settlement website was September 14, 2026, which has passed; the final approval hearing is set for October 13, 2026, and final approval had not been granted in the docket reviewed. Whether a late claim will be considered is not stated on the pages reviewed. Official website: chantixsettlement.com; administrator (A.B. Data, Ltd.) helpline 1-877-354-3912 and [email protected].
• Depo-Provera (medroxyprogesterone acetate) injury claims. These are being handled in a federal multidistrict litigation (MDL No. 3140, N.D. Fla.). This is an individual-case settlement, not an open consumer class-claim form: a court order of July 27, 2026 records that a private Master Settlement Agreement was signed July 21, 2026, that it is not a class action and "is not subject to a fairness determination by the Court," and that eligibility "is defined within the MSA." The court's docket shows settlement administrators appointed in August and September 2026. The docket entries reviewed do not publish a claim form, filing deadline or self-enrollment instructions; the parties told the court that settlement registration should be completed in November 2026. Questions about eligibility go to the attorney handling the claim.

Complaints on this site are unverified user reports. Nothing here is medical or legal advice; questions about a specific medicine belong with a healthcare provider or pharmacist.

FDA recalls, safety communications, DOJ settlement and government inquiries

FDA recalls of Pfizer retail (patient-level) medicines

• Chantix (varenicline). On July 16, 2021 Pfizer announced it was "voluntarily recalling two lots of Chantix 0.5mg Tablets, two lots of Chantix 1 mg Tablets, and eight lots of a Chantix kit of 0.5mg/1 mg Tablets to the patient (consumer/user) level due to the presence of a nitrosamine, N-nitroso-varenicline, above the Pfizer established Acceptable Daily Intake (ADI) level" (FDA published it July 19, 2021). On September 16, 2021 Pfizer expanded the recall to "all lots of Chantix 0.5 mg and 1 mg Tablets", saying "As alternative suppliers have been approved in the United States, Pfizer is undertaking this precautionary measure." Both notices state that long-term ingestion "may be associated with a theoretical potential increased cancer risk in humans, but there is no immediate risk to patients taking this medication," and that "The health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline." The September 2021 notice told patients to contact Stericycle at 888-276-6166 for return instructions and reimbursement. Pfizer's FY2025 Form 10-K says that after updated regulatory guidance on acceptable intake limits, "in 2025, Chantix returned to market in the U.S."
• Accuretic and authorized generics (quinapril/hydrochlorothiazide). Announced March 21, 2022 (FDA published March 22): six lots of Accuretic, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/hydrochlorothiazide tablets (the last two distributed by Greenstone) recalled "to the patient (consumer/user) level due to the presence of a nitrosamine, N-nitroso-quinapril, above the Acceptable Daily Intake (ADI) level."
• Accupril (quinapril). Announced April 22, 2022: five lots of Accupril 10 mg, 20 mg and 40 mg tablets, recalled to the patient level for the same N-nitroso-quinapril reason. Both quinapril notices say "Pfizer is not aware of reports of adverse events that have been assessed to be related to this recall."
• Levoxyl (levothyroxine) 50 mcg, 100-count bottles. FDA's Enforcement Report (openFDA data, recall D-0575-2025) lists a Class II voluntary, firm-initiated recall for "Subpotent drug", lot 24C11 (expiry 2/28/2026, a date that has passed), initiated July 29, 2025 and reported August 20, 2025; 29,004 bottles, distributed within the U.S. FDA's status field read "Ongoing" in the record retrieved on September 30, 2026; that is a field in FDA's enforcement record, not a statement about whether the lot remains on sale.
• Bicillin L-A (penicillin G benzathine injectable suspension), 1,200,000 units per 2 mL and 2,400,000 units per 4 mL. Enforcement Report entries D-0544-2025 and D-0545-2025: Class II, reason "CGMP Deviations; particulates identified during visual inspection", 12 lots across the two entries (7 and 5 lots), initiated July 10, 2025 and reported August 6, 2025; nationwide; the records list quantities of 50,855 and 19,279 vials respectively. FDA's status field read "Ongoing" in both records retrieved on September 30, 2026 (an enforcement-record status).

How these numbers were obtained. The Enforcement Report entries above and the counts here come from FDA's openFDA Enforcement Report API, queried on September 30, 2026 (dataset last updated September 23, 2026) with search=recalling_firm:"Pfizer" AND report_date:[20210101 TO 20260930], limit=100 (the exact URL is in the sources list). The query matches the recalling-firm field. It returned 44 records that group into 22 distinct event IDs; each event was counted once by its record's classification field: 7 Class I, 14 Class II and 1 Class III. The most recent record was reported September 23, 2026 (dopamine HCl injection 200 mg/5 mL, distributed by Hospira, Inc., lot NL5230, Class II, "Lack of Assurance of Sterility", recall initiated September 4, 2026). What the classes mean: FDA defines a Class I recall as "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death," Class II as "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," and Class III as "a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences." A class shows the relative degree of health hazard FDA assigns to a recalled product; it is not a finding of fault and not proof that anyone was injured. The product descriptions of all seven Class I events name Hospira (sodium bicarbonate, lidocaine, propofol, vancomycin, bupivacaine and bleomycin injections). FDA's Enforcement Reports page says the classification and posting "should not be seen as an expansion or change to a firm's voluntary public warning."

FDA safety communications and label changes

• Depo-Provera CI and depo-subQ provera 104. FDA's approval letter, electronically signed December 12, 2025, approves a supplement that "provides for the addition of information related to Meningioma risk in Section 5 Warnings and Precautions, Section 17 Patient Counseling Information and the corresponding sections in the Patient Information." The approved label states: "Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma. Discontinue Depo-Provera CI if a meningioma is diagnosed." That is label language addressed to prescribers; a patient with questions about this warning should talk to the prescribing clinician and should not stop a medicine without medical advice. The letter refers to Pfizer's June 12, 2025 amendment as "a complete response to our November 1, 2024, action letter."
• Oxbryta (voxelotor). FDA alert dated 9/26/2024: Pfizer "is voluntarily withdrawing the medication from the market, ceasing distribution, and discontinuing all active clinical trials and expanded access programs for Oxbryta because recent data indicate the benefit of Oxbryta does not outweigh the risks for the sickle cell patient population." FDA said Pfizer reported "a higher rate of vaso-occlusive crisis" and "more deaths in the Oxbryta treatment group as compared to the placebo group" in postmarketing studies, and that patients "should contact their health care professional about stopping Oxbryta and starting another treatment option." Pfizer's Q2 2026 Form 10-Q states that "On July 31, 2026, Pfizer notified the FDA that it is voluntarily withdrawing the NDAs for Oxbryta" and, in explaining a $525 million impairment, that after Pfizer engaged with FDA in July 2026 "it was determined there was no viable pathway to return Oxbryta to the market in the U.S."
• Xeljanz and Xeljanz XR (tofacitinib). FDA Drug Safety Communication of September 1, 2021: "Based on a completed U.S. Food and Drug Administration (FDA) review of a large randomized safety clinical trial, we have concluded there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death" with the medicine. FDA's December 2021 update says the issues "have been addressed in product labeling."

U.S. Department of Justice. On January 24, 2025 DOJ announced that Pfizer, "on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), has agreed to pay $59,746,277" to resolve allegations that Biohaven paid kickbacks, including speaker honoraria and meals, to induce prescriptions of Nurtec ODT between March 1, 2020 and September 30, 2022. DOJ says the conduct it alleges "persisted until October 2022, when Pfizer acquired Biohaven and terminated the Nurtec speaker programs," that about $50.2 million is the federal share and about $9.5 million the state Medicaid share, and that "The claims resolved by the settlement are allegations only and there has been no determination of liability."

Other government matters Pfizer disclosed in its SEC filings (disclosures of inquiries and lawsuits, not findings). The Q2 2026 Form 10-Q (Note 12, A4, Government Investigations) describes: complaints filed in 2019 and 2020 by Attorneys General of more than 50 states and territories in the U.S. District Court for the District of Connecticut against a number of pharmaceutical companies including Pfizer and Greenstone (a former Pfizer subsidiary), alleging anticompetitive conduct; and an informal request from DOJ's Consumer Protection Branch (March 2020) and a similar request from the U.S. Attorney's Office for the SDNY (April 2020, a civil investigation) about operations in India. The FY2025 Form 10-K (Note 16, A4) also describes: an October 2018 SDNY subpoena about Pfizer's relationship with another drug manufacturer and Quillivant XR (in June 2025 the SDNY and related states declined to intervene in a qui tam action, which the relator pursues in his individual capacity); a February 2019 SDNY Civil Investigative Demand and an August 2019 HIPAA subpoena from the U.S. Attorney's Office for the Eastern District of Missouri (in coordination with DOJ's Consumer Protection Branch) about alleged quality issues with auto-injectors at the former Meridian site; an April 2023 HIPAA subpoena from the U.S. Attorney's Office for the Western District of Virginia (in coordination with DOJ's Commercial Litigation Branch) about Pfizer-sponsored programs in retail pharmacies relating to Xeljanz; and Zantac civil actions by the State of New Mexico and the Mayor and City Council of Baltimore. The Q2 2026 Form 10-Q does not repeat the items described only in the 10-K. Pfizer states that it has produced records in response to these requests.

Who Pfizer is and how it is organized

Pfizer Inc. is a Delaware corporation, incorporated June 2, 1942 according to its Form 10-K, with principal executive offices at 66 Hudson Boulevard East, New York, NY 10001-2192 and shares listed on the New York Stock Exchange (PFE). The company says it was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn. Its 10-K states that "Most of our revenues come from the manufacture and sale of biopharmaceutical products."

Pfizer sells through subsidiaries and divisions. FDA records show Pfizer-labeled products "Distributed by Pfizer Labs, Division of Pfizer Inc." and by "Parke-Davis Division of Pfizer." Pfizer's SEC filings describe Warner-Lambert (acquired 2000) and Pharmacia (acquired 2003) as wholly owned subsidiaries; DOJ describes Biohaven as a wholly owned subsidiary. Pfizer's 10-Q states that in 2006 it sold its consumer business, including its Zantac OTC rights, to Johnson & Johnson.

Patient assistance. Pfizer RxPathways says the Pfizer Patient Assistance Program "Provides free Pfizer medicines to eligible patients through their doctor's office or at home" and is "a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation," which "is a separate legal entity from Pfizer Inc." The company's homepage claim is that "Over 26,000 Patients Received over 160,000 Pfizer prescriptions for free in 2025" (company data on file, not independently verified). Pfizer also lists treatment-specific support hubs for many brands and co-pay and savings offers.

Counterfeit medicines. Pfizer's Counterfeiting page (company statements, read September 30, 2026) says: "Counterfeit versions of at least 104 Pfizer medicines have been confirmed in more than 116 countries." The page says "Reputable online pharmacies will ask for a prescription issued by a relevant healthcare professional and provide adequate warnings about the possible side effects of the drug," and that counterfeit medicines have entered the supply chain even in countries such as Canada, the United States and many EU members. FDA's BeSafeRx page lists "Does not require a doctor's prescription" among the warning signs of an unsafe online pharmacy and says a safe one "Is licensed with a state board of pharmacy." Questions about a specific product belong with a pharmacist or healthcare provider; Pfizer's Contact Us page and FDA MedWatch are places to report a suspect product.

Complaint record on this site and other public profiles

This site has 11 approved user complaints in which Pfizer is the named subject, all published between 2006 and 2012. They concern tetracycline-related tooth staining (5 posts), rebate or co-pay offer terms (3), the Pfizer patient-assistance income limit (1), a Depo-Provera post (1) and an employment discrimination claim (1). Another 11 posts are linked to the Pfizer page but are not counted as complaints about Pfizer: five describe emails, checks or job offers that use Pfizer's name (the posters ask whether they are genuine), one concerns a Listerine product, and five concern Spiriva capsules. These posts are user statements that the site has not verified, and they describe products and programs as they were up to 2012.

Other public profiles (each is reported separately and not combined):

• BBB: the profile for Pfizer Inc., New York (listed at 235 East 42nd Street; BBB file opened September 30, 1999) shows rating A+ and "NOT a BBB Accredited Business." Its complaints tab says "9 total complaints in the last 3 years. 1 complaint closed in the last 12 months." The reviews tab shows an average of 1/5 from 2 customer reviews (November 2025 and February 2024). BBB's profile also carries a notice about the May 13, 2019 multistate lawsuit over generic drug prices, which BBB describes as "a pending government action" whose allegations "have not yet been proven."
• Trustpilot (pfizer.com): unclaimed profile, 52 reviews with a 1.9 out of 5 score, 10 reviews in the last 12 months; the profile carries Trustpilot's label "No history of asking for reviews" and the notice "This company hasn't invited their customers, so reviews may not be representative."
• ComplaintsBoard: the Pfizer page (updated May 18, 2026) lists 100 complaints (15 marked resolved and 85 unresolved) and 1 review, which the page's summary shows as a 1.6-star rating; these are user-submitted and unverified.

Depo-Provera, Chantix, Zantac and other litigation

Depo-Provera (medroxyprogesterone acetate) - MDL No. 3140, U.S. District Court, N.D. Florida. Plaintiffs allege that use of injectable Depo-Provera for contraception caused meningioma. Pfizer's filings say federal cases were transferred to an MDL in the Northern District of Florida in February 2025 and that coordinated state proceedings exist in California, Connecticut, Delaware and New York. The docket (In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, 3:25-md-03140, Judge M. Casey Rodgers, Magistrate Judge Hope T. Cannon) names Pfizer Inc., Pharmacia LLC and Pharmacia & Upjohn Co LLC as defendants. Status from the docket as of the entries reviewed on September 30, 2026:

• The court organized the threshold issues around Pfizer's federal preemption defense and Pfizer's position that plaintiffs lack reliable expert evidence of general causation, using five Pilot Cases (Pretrial Order No. 30, January 27, 2026). Preemption arguments were heard September 29, 2025; the court then asked for supplemental briefing after FDA approved the meningioma warning on December 12, 2025.
• Pfizer's Form 10-Q says that "In June 2026, we reached an agreement-in-principle with plaintiff leadership in the Depo-Provera MDL that we expect to resolve a substantial majority of the pending MDL cases on terms that are not material to the Company's liquidity or financial condition." Pretrial Order No. 30A (June 15, 2026) describes a "global agreement" under which "all Plaintiffs with cases pending in the MDL who meet the eligibility criteria agreed to by the Parties will have an opportunity to resolve their claims," says the court "will postpone ruling on Defendants' pending Motion for Summary Judgment Based on Federal Preemption," and notes that the agreement "will not resolve all cases in the MDL." Case Management Order No. 12 (July 27, 2026, ECF 701) then records: "A Master Settlement Agreement (“MSA”) was signed by the Parties on July 21, 2026," with the parties estimating "that roughly 80% of all MDL Plaintiffs will be eligible." The order calls it "a private agreement governed by a confidentiality agreement," says eligibility "will not be impacted by any future Court ruling on the legal issues that remain outstanding in the MDL," and states: "The Settlement is not subject to a fairness determination by the Court because this MDL is not a class action." The parties represented that settlement registration should be completed in November 2026, with payments beginning to roll out by the first quarter of 2027, and the court approved a no-filing-fee administrative docket. The court added that it will rule on preemption and general causation for cases that are ineligible for the settlement or opt out.
• Case Management Orders followed: No. 13 (August 5, 2026, ECF 711, "Appointment of Settlement Administrator"; docket entries refer to a BrownGreer affidavit deadline of August 12 and a settlement-administrator affidavit filed August 13, 2026), No. 14 (August 10, 2026, ongoing litigation), Nos. 15, 16 and 17 (September 4, 2026: a Supplemental Compensation Fund Allocation Master, a Qualified Settlement Fund Administrator and BrownGreer PLC as Lien Resolution Administrator) and No. 18 (September 15, 2026, "Establishment of Administrative Docket in Connection with Settlement"). Orders 13 to 18 were read from docket text only; their full text was not available in the free CourtListener archive.
• On September 15, 2026 the court referred Pfizer's summary-judgment motion on federal preemption (ECF 413, filed August 22, 2025) to Magistrate Judge Hope T. Cannon for a report and recommendation under Rule 72(b) (ECF 762).
• The court held the general causation (Rule 702) hearing on September 18, 2026 (minute entry ECF 765: "Testimony and argument heard, order to follow"; a notice of the official hearing transcript was filed September 24, 2026). An order entered September 24, 2026 canceled the October 16 and November 20, 2026 case management conferences and requires written status updates on October 16, November 20 and December 14, 2026.
• The settlement amount and detailed eligibility criteria are not public in the docket entries reviewed (the July 27 order describes the MSA as governed by a confidentiality agreement), and those entries do not include a claim form, filing deadline or self-enrollment instructions. Because the MDL is not a class action, no class-style final approval order is expected; the MDL itself remains pending and no judgment or dismissal of it was found. CourtListener showed September 25, 2026 as the last known filing when the docket was read on September 30, 2026; CourtListener is not PACER.

Chantix (varenicline) - MDL No. 3050, U.S. District Court, S.D.N.Y. (Judge Katherine Polk Failla). Putative class actions filed from August 2021 after the recall allege economic harm from buying Chantix. The class settlement website says: "Pfizer will pay $44,000,000.00 to the Settlement Class Members" and that "Pfizer believes it did nothing wrong and denies that it violated any law but has agreed to the Settlement to avoid the uncertainties and expenses associated with continuing the case." The class covers individuals and third-party payors who paid any amount for retail Chantix purchases in the U.S. and territories from September 29, 2015 through September 17, 2021. Consumer payments are pro rata, capped at 20% of the Available Settlement Fund and never more than the amount paid; the remainder goes to third-party payors; class counsel will seek no more than one-third of the fund in fees. The court granted preliminary approval on June 1, 2026 (ECF 133). On June 26, 2026 it extended the dates by two weeks: claims, exclusions and objections by September 14, 2026 (passed), and the final approval hearing on October 13, 2026 at 3:00 p.m., Courtroom 618, 40 Foley Square. The docket lists an "Attorney Fees" filing with a memorandum of law and a declaration on August 28, 2026 (ECF 139-141), and on September 28, 2026 a letter, a "Miscellaneous Relief" entry, a memorandum of law in support of a motion, two declarations and a proposed judgment (ECF 142-147); those documents are behind PACER and were not read. No final approval order had been entered in the docket reviewed (last known filing September 28, 2026). The settlement website adds: "Please note that the fairness hearing date is subject to change without further notice." Administrator: A.B. Data, Ltd., helpline 1-877-354-3912, [email protected].

Zantac (ranitidine). Pfizer's filings state that it "has not sold Zantac since 2006, and only sold an OTC version of the product," and that in 2006 it sold the consumer business including its Zantac OTC rights to Johnson & Johnson and transferred the related assets and liabilities. Lawsuits against Pfizer allege cancer from Zantac; the federal MDL in the Southern District of Florida (MDL No. 2924) granted defendants' expert and general-causation motions in December 2022, "which has resulted in the dismissal of all complaints in the litigation," and Pfizer's August 2026 10-Q says plaintiffs have appealed (the appellate docket was not located: a CourtListener RECAP case-name search for Zantac in the Eleventh Circuit on September 30, 2026 returned no docket for the plaintiffs' appeal, and an opinions search returned five unpublished orders, the newest dated February 23, 2024; CourtListener does not cover every filing, so this is a limit of the search). As of May 2026 Pfizer said it had settled or agreed in principle to settle "a substantial majority" of state-court cases alleging use of a Pfizer product.

State of Texas v. Pfizer. The Texas Attorney General sued in 2023 alleging Pfizer misrepresented COVID-19 vaccine efficacy; those claims are allegations. The U.S. District Court for the Northern District of Texas (No. 5:23-CV-312) granted Pfizer's motion to dismiss in an order filed December 30, 2024. The order says Pfizer "is entitled to immunity under the Public Readiness and Emergency Act," that both the PREP Act and the Food, Drug, and Cosmetic Act preempt the State's claims, and that the alleged statements "were not connected to any “trade or commerce” or any “consumer transaction.”" The Attorney General's January 8, 2025 release describes the ruling as the judge "claiming that the federal government had given Pfizer immunity through the Public Readiness and Emergency Act" and says Texas noticed an appeal. The Fifth Circuit docket (No. 25-10182) shows a January 28, 2026 order granting the parties' joint motion to postpone oral argument and hold the appeal in abeyance pending the Supreme Court's resolution of Chevron U.S.A. Inc. v. Plaquemines Parish (No. 24-813); oral argument was heard September 1, 2026 before Judges Jones, Southwick and Willett, and no decision appeared in the docket reviewed.

Search limitation (Oxbryta). A CourtListener case-name search for Oxbryta on September 30, 2026 returned no case. CourtListener does not cover PACER or state courts completely, so this shows only what that search returned; it is not a statement that no such case exists. The SEC filings reviewed do not describe Oxbryta injury litigation.

Is Pfizer Legitimate?

Pfizer Inc. is an SEC-registered public company (CIK 0000078003) that filed its FY2025 Form 10-K on February 26, 2026 and a Form 10-Q on August 4, 2026, is incorporated in Delaware, has its principal executive offices in New York and is listed on the NYSE under PFE. FDA records, recalls and label approvals cited on this page are issued to Pfizer Inc. under its own name.

Registration and listing say nothing about whether an individual complaint is justified. The complaints, lawsuits and government inquiries on this page are allegations unless a court or agency has found otherwise, and Pfizer's position is noted where a court filing or settlement notice states it. Some posts on this site describe emails, checks or job offers that use Pfizer's name; Pfizer's Contact Us page is the company's published channel for inquiries.

Court & Public Records

Related Complaints

Names this company in a role other than the primary subject — not necessarily current or complete.

• Named as a brand of this company: I had to throw out 3 dosages yesterday as they did not work
• Named as a brand of this company: Consumer Report
• Named as a brand of this company: Spriva Amount in Capsule
• Named as a brand of this company: Reciving an unwanted email as a job offer in Pfizer Pharmaceuticals LTD, UNITED KINGDOM
• Named as a brand of this company: Empty capsules
• Named as a brand of this company: Spiriva Inhale
• Named as a brand of this company: Listerine Disappearing Listerine Whitener 235 East 42nd Street
• Named as a brand of this company: Recieved a check in the amout of 2980.00 looks real
• Named as a brand of this company: They sent me a check for 2980.00 said I won sweepstakes for 65,000.00 dollars
• Named as a brand of this company: Appointment lette
• Named as a brand of this company: Pfizer/Lilly Spam

Company Relationships

• Affiliated with: Pharmacia LLC
• Affiliated with: Warner-Lambert
• Affiliated with: Biohaven Pharmaceutical Holding Company Ltd.
• Affiliated with: Greenstone

Frequently Asked Questions